734 results on '"Hjemdahl, Paul"'
Search Results
2. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention
3. Importance of Creatinine for Urine Quality Control in Determination of Abused Drugs
4. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants
5. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease
6. Ethical Aspects of Measuring Adherence to Antihypertensive Treatment
7. Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non–Vitamin K Oral Anticoagulants
8. Abstract P430: Role of Cystatin C-based Estimated Glomerular Filtration Rate for Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation
9. Concluding Remarks
10. Haemostatic Effects of Stress
11. Cardiovascular and Autonomic Responses to Stress
12. Introduction to Cardiovascular Disease, Stress and Adaptation
13. Ethical Aspects of Measuring Adherence to Antihypertensive Treatment
14. Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
15. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
16. On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation
17. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants: The Stockholm Experience
18. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
19. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system
20. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
21. Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease
22. Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials
23. MO514: Cardiorenal Outcomes Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation
24. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
25. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
26. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
27. Oral anticoagulants in patients with atrial fibrillation at low stroke risk : a multicentre observational study
28. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
29. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
30. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA2DS2VASc scores: experience from the Stockholm region
31. Heart rate variability in patients with angina pectoris
32. Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease
33. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
34. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
35. Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021
36. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
37. Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
38. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
39. Association of Preceding Antithrombotic Therapy in Atrial Fibrillation Patients With Ischemic Stroke, Intracranial Hemorrhage, or Gastrointestinal Bleed and Mortality
40. Regional variation and adherence to guidelines for drug treatment of asthma
41. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease
42. Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021
43. Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding
44. Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems : report by an international expert workshop at Karolinska Institutet
45. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
46. Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding
47. Pharmacological Prevention of Reperfusion Injury in Acute Myocardial Infarction: A Potential Role for Adenosine as a Therapeutic Agent
48. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis: Results of theATTenuation byAdenosine ofCardiacComplications (ATTACC) study
49. Hemodynamic and sympathoadrenal responses to mental stress during nitric oxide synthesis inhibition
50. Risk prediction in stable angina pectoris
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.